INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $800,311 | -15.7% | 15,364 | +2.5% | 0.00% | -25.0% |
| Q2 2023 | $949,357 | +28.7% | 14,993 | +10.0% | 0.00% | +33.3% |
| Q1 2023 | $737,794 | -6.1% | 13,625 | -8.2% | 0.00% | -25.0% |
| Q4 2022 | $785,439 | +109.5% | 14,842 | +84.3% | 0.00% | +100.0% |
| Q3 2022 | $375,000 | +29.3% | 8,054 | -11.8% | 0.00% | +100.0% |
| Q4 2020 | $290,000 | -50.1% | 9,132 | -82.1% | 0.00% | -75.0% |
| Q4 2018 | $581,000 | -62.8% | 51,030 | -29.0% | 0.00% | -50.0% |
| Q3 2018 | $1,560,000 | -11.2% | 71,905 | -27.6% | 0.01% | -20.0% |
| Q2 2018 | $1,756,000 | +132.9% | 99,370 | +63.7% | 0.01% | +100.0% |
| Q2 2017 | $754,000 | – | 60,720 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |